QCI Interpret for Oncology
Comprehensive Molecular Tumor Analysis with Alacris Theranostics
369 views
Alacris Theranostics developed the Comprehensive Molecular Tumor Analysis (CMTA), a NGS-based tumor diagnostic test. The test integrates whole exome and transcriptomic sequencing (WES and RNAseq). The test deploys as an end-to-end accredited diagnostic platform from tumor sample uptake (FFPE or frozen) to personalized clinical interpretation reports. CMTA is a tumor-agnostic test that displays a unique molecular view of each sample. CMTA is a useful approach for refractory cancers with complex patterns or tumors of unknown origin.
In this webinar, viewers will:
Learn about the strategy implemented in Alacris’ bioinformatics pipeline to identify cancer-relevant somatic events
Learn how Alacris uses QCI Interpret for Oncology to annotate variants and identify potential therapies
Be eligible for a complimentary QCI Interpret demo and sample report
Related videos
QCI Interpret for Oncology
Real-World Applications of Clinical Metagenomic Sequencing in Cancer and Infectious Disease...
Clinical metagenomic next-generation sequencing (mNGS), the comprehensive...
QCI Interpret for Oncology
Clinician’s Roundtable: Interpreting genomic test results for precision oncology
You’re invited to attend the 2024 Clinician’s Roundtable, a virtual event...
QCI Interpret for Oncology
Agilent Alissa to QCI Interpret: How can your lab reduce the stress and complexity of...
In 2023, Agilent announced the discontinuation of their Alissa Interpret...
QCI Interpret for Oncology
Scale your comprehensive genomic profiling workflow with superior automated variant interpretation
Automating and scaling a comprehensive genomic profiling workflow can be a...